Bryce Point Capital, LLC Ultragenyx Pharmaceutical Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 10,719 shares of RARE stock, worth $465,526. This represents 0.13% of its overall portfolio holdings.
Number of Shares
10,719Holding current value
$465,526% of portfolio
0.13%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
333Shares Held
86.8MCall Options Held
543KPut Options Held
436K-
Vanguard Group Inc Valley Forge, PA10MShares$436 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$243 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$222 Million0.91% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$133 Million0.02% of portfolio
-
Alkeon Capital Management LLC New York, NY3.01MShares$131 Million0.29% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.04B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...